Pharmacies will no longer be the exclusive retailers for allergy medicine, Telfast (fexofenadine) following a Therapeutic Goods Administration (TGA) decision to de-schedule the product.
The decision comes after a recommendation from the Advisory Committee on Medicines Scheduling to exempt small packs of 10 dosage units or less of the 120mg/day version of Telfast from scheduling.
Speaking to Pharmacy News after the ACMS recommendation was announced in April, Tim Logan, president of the Pharmacy Guild of Australia (Queensland branch), said pharmacists would start recommending alternative Pharmacy-Only products to Telfast that were equally therapeutically valid.
He also dismissed the suggestion that making the medicine exempt from scheduling would make it more accessible to consumers.
“In terms of convenience, with the number of out-of-hours pharmacies around the...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.